Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
Avalo Therapeutics Files Prospectus For Offering $200M Common Shares
Avalo Therapeutics Q3 EPS $(0.34) Beats $(0.61) Estimate
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3
Guggenheim Downgrades Avalo Therapeutics to Neutral
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22
HC Wainwright & Co. Downgrades Avalo Therapeutics to Neutral
BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.